Holen Sie sich die Stockscreener-App
91.65
2.17%
1.95
Vorhandelsmarkt:
91.35
-0.30
-0.33%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$89.70
Offen:
$89.97
24-Stunden-Volumen:
7.46M
Relative Volume:
0.98
Marktkapitalisierung:
$117.43B
Einnahmen:
$33.54B
Nettoeinkommen (Verlust:
$4.66B
KGV:
25.32
EPS:
3.62
Netto-Cashflow:
$5.19B
1W Leistung:
+2.72%
1M Leistung:
+6.15%
6M Leistung:
+4.34%
1J Leistung:
+15.57%
1-Tages-Spanne:
$89.81
$91.92
1-Wochen-Bereich:
$88.35
$91.92
52-Wochen-Spanne:
$78.32
$96.25
Medtronic Plc Stock (MDT) Company Profile
Firmenname
Medtronic Plc
Sektor
Branche
Telefon
01135314381700
Adresse
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Vergleichen Sie MDT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
91.65 | 114.31B | 33.54B | 4.66B | 5.19B | 3.62 |
|
ABT
Abbott Laboratories
|
125.73 | 228.77B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.16 | 153.09B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
395.15 | 149.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
EW
Edwards Lifesciences Corp
|
76.30 | 45.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-10-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-08-21 | Bestätigt | Oppenheimer | Perform |
| 2024-08-15 | Hochstufung | UBS | Sell → Neutral |
| 2024-08-14 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Sell |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-29 | Herabstufung | UBS | Buy → Sell |
| 2023-01-09 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-11-23 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-11-23 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-08-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-06-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-27 | Herabstufung | Needham | Buy → Hold |
| 2022-04-13 | Herabstufung | Truist | Buy → Hold |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-10 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-12-16 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-10 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-12-15 | Hochstufung | Goldman | Sell → Neutral |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-10-08 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-10-08 | Hochstufung | Stifel | Hold → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-05-14 | Herabstufung | DZ Bank | Buy → Hold |
| 2020-03-30 | Herabstufung | Needham | Strong Buy → Buy |
| 2020-03-25 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Sell |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-02 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-06-05 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-02-04 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-08-27 | Bestätigt | Argus | Buy |
Alle ansehen
Medtronic Plc Aktie (MDT) Neueste Nachrichten
What drives Medtronic plc stock priceExplosive capital appreciation - Autocar Professional
Medtronic plc Stock Analysis and ForecastDynamic growth stocks - Autocar Professional
Is Medtronic plc a good long term investmentJaw-dropping returns - jammulinksnews.com
Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know - Nasdaq
What analysts say about Medtronic plc stockTurbocharged investment results - jammulinksnews.com
Medtronic gets EU nod for MiniMed 780G System - MSN
Medtronic’s (MDT) Role in Medical Devices: A Unique Fit for Halal Portfolios - MSN
Published on: 2025-07-22 10:22:55 - jammulinksnews.com
Medtronic (MDT): A Shariah-Compliant Powerhouse in the Evolving Medical Device Sector - AInvest
Medtronic MiniMed 780G wins CE mark for type 2 diabetes, young children - MassDevice
Court Nixes Jury Award Over Medtronic's Heart Valve Infringement ClaimMedtronic (NYSE:MDT) - Benzinga
Medtronic gets EU nod for MiniMed 780G System (MDT:NYSE) - Seeking Alpha
Medtronic (MDT) Expands MiniMed 780G System Indications with Eur - GuruFocus
Medtronic expands MiniMed 780G system indications across Europe - Investing.com Australia
Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes - Medtronic
10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever - The Motley Fool
Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict - MassDevice
Fed. Circ. Frees Medtronic From $125M Patent Judgment - Law360
Medtronic wins appeal to avoid $106.5M patent verdict (MDT:NYSE) - Seeking Alpha
Medtronic wins US appeal to overturn $106.5 mln heart-valve patent verdict - Reuters
Breaking Barriers: Medtronic and Zverev Unite - Il Messaggero
Medtronic’s SWOT analysis: renal denervation, diabetes spin-off to drive stock - Investing.com
Medtronic enrolls first patient in study for Onyx liquid embolic system - MassDevice
Analyst Expectations For Medtronic's Future - Benzinga
Got Their Backs: How Medtronic Brings Spine Surgeries to Kids - Yahoo Finance
Medtronic gets CE mark for robot-driven vessel-sealing device - MedTech Dive
Baird Adjusts Medtronic Price Target to $94 From $92, Maintains Neutral Rating - MarketScreener
Morgan Stanley Adjusts Medtronic Price Target to $107 From $98, Maintains Overweight Rating - MarketScreener
Medtronic : first in the U.S. to offer 400 cm 0.018” peripheral guidewire for transradial access - MarketScreener
Medtronic, Renal Denervation, and the Power of Persistence - Medical Device and Diagnostic industry
Medtronic (MDT) Price Target Raised by Morgan Stanley | MDT Stoc - GuruFocus
Medtronic shaping future of surgery, secures CE Mark for LigaSure™ technology on Hugo™ robotic-assisted surgery system - Medtronic
Medtronic (MDT) Experiences Increased Bearish Options Activity | MDT Stock News - GuruFocus
Prostate Care Market Report 2025-2031 | Medtronic, Johnson & Johnson, Boston Scientific, and Abbott Laboratories Dominate through Product Innovations, Clinical Trials, M&As, and Strategic Partnerships - Yahoo Finance
Medtronic Stock Is Climbing Friday: What's Going On?Medtronic (NYSE:MDT) - Benzinga
Medtronic (MDT) Stock Insights and Investment Tools | MDT Stock News - GuruFocus
Medtronic (MDT) Gains from CMS Proposal on Renal Denervation Coverage | MDT Stock News - GuruFocus
Medtronic Says Centers for Medicare & Medicaid Services Proposes National Coverage for Blood Pressure Treatment Device - MarketScreener
Unusual Options Activity Noticed for Medtronic (MDT) | MDT Stock News - GuruFocus
Medtronic (MDT) Set for Growth with Proposed Coverage for Renal Denervation | MDT Stock News - GuruFocus
Medtronic (MDT) Gains Following Medicare's Review of New Hypertension Technology | MDT Stock News - GuruFocus
William Blair reiterates Market Perform rating on Medtronic stock after CMS proposal - Investing.com
Medtronic, Recor praise new CMS coverage for renal denervation - MassDevice
Medtronic : issues statement on the U.S. Centers for Medicare & Medicaid Services proposed National Coverage Determination for Symplicity Spyral™ renal denervation (RDN) system - MarketScreener
Citi Analyst Boosts Medtronic (MDT) Price Target to $99 | MDT Stock News - GuruFocus
Needham Keeps Hold Rating on Medtronic (MDT) Amid Spin-Off News - MSN
Finanzdaten der Medtronic Plc-Aktie (MDT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):